Oxford University and Moderna to trial pioneering cancer vaccine

• A pioneering cancer vaccine , developed by the University of Oxford and Moderna , is scheduled to undergo trials this summer.
• The jab targets patients with Lynch syndrome, who are at high risk of developing bowel and ovarian cancer .
• The study aims to investigate the vaccine’s ability to train the immune system to identify and eliminate pre-cancerous cells in people with Lynch syndrome, aiming to prevent cancer from developing.
• The initiative represents Moderna's first venture into cancer prevention with its mRNA technology, while Oxford experts believe the approach could be adapted for other cancer types in the future.
• The initial Intercept-Lynch trial will assess immune responses, optimal dosage, and safety, with a second phase expected to commence in 2027.

IN FULL

Oxford University and Moderna launch trials of vaccine that could prevent cancer